Wie hoch ist der Preis für OptiNose, Inc. (OPTN)

Preis für OptiNose, Inc. (OPTN) ist $9.60

Wie hoch ist die Marktkapitalisierung für OptiNose, Inc. (OPTN)

Marktkapitalisierung für OptiNose, Inc. (OPTN) ist $1.08B

OptiNose, Inc. (OPTN) Ausstehende Aktien

OptiNose, Inc. is a specialized pharmaceutical company primarily focused on innovating and bringing to market treatments for individuals under the care of ear, nose, throat, and allergy specialists throughout the United States. Its flagship product, XHANCE, utilizes the company's proprietary exhalation delivery system (EDS) to administer a topically-acting corticosteroid. This therapy is approved for treating chronic rhinosinusitis when accompanied by nasal polyps and is currently undergoing Phase IIIb clinical trials for broader chronic sinusitis treatment. The company also offers Onzetra Xsail, a powder-based EDS device, which is commercialized via a licensing agreement with Currax Pharmaceuticals LLC. Further expanding its pipeline, OptiNose is developing OPN-019, an investigational product that integrates a liquid EDS device with an antiseptic agent. Additionally, OptiNose has formed a partnership with Inexia Limited. This collaboration centers on the development, manufacturing, importation, and sale of products containing orexin receptor agonist or positive modulator molecules, intended for the treatment, diagnosis, or prevention of human conditions predominantly linked to orexin receptor activity. Established in 2000, OptiNose, Inc. operates from its corporate headquarters in Yardley, Pennsylvania.

Jahr	Ausstehende Aktien	ändert
2026 (TTM)	11.67M	14.88%
2024	10.16M	-90.94%
2023	112.08M	1,857.16%
2022	5.73M	-89.93%
2021	56.85M	17.77%
2020	48.28M	15.28%
2019	41.88M	5.31%
2018	39.77M	18.80%
2017	33.47M	1,131.11%
2016	2.72M	-89.82%
2015	26.72M	0.00%

Jahr

Ausstehende Aktien

ändert

2026 (TTM)

11.67M

14.88%

2024

10.16M

-90.94%

2023

112.08M

1,857.16%

2022

5.73M

-89.93%

2021

56.85M

17.77%

2020

48.28M

15.28%

2019

41.88M

5.31%

2018

39.77M

18.80%

2017

33.47M

1,131.11%

2016

2.72M

-89.82%

2015

26.72M

0.00%

Unternehmen	Ausstehende Aktien	Unterschied	Land
MERCK Kommanditgesellschaft auf Aktien MER.SW	-	-	DE
Merck KGaA MRK.DE	-	-	DE
Takeda Pharmaceutical Company Limited 4502.T	-	-	JP
Galderma Group AG GALD.SW	-	-	CH
Sun Pharmaceutical Industries Limited SUNPHARMA.NS	2.40B	20,463.38%	IN

Unternehmen

Ausstehende Aktien

Unterschied

Land